Payment overview · 2025
General Payments
$83.89
4 reported records · 4 companies
Healthcare provider profile · identity verified
Samuela Eudora Manages, MD
Allopathic & Osteopathic Physicians|Family Medicine|Addiction Medicine · VAN BUREN, ME · NPI 1750549044
Verified facts
What the public records show
CMS Open Payments records show Samuela Eudora Manages, MD received $83.89 in general payments during 2025 across 4 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 29.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $24.44 | 29.1% | 1 | 2025 |
| Braeburn Inc. | Unresolved — no canonical attribution shown | $20.49 | 24.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $20.39 | 24.3% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $18.57 | 22.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $83.89 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $24.44 | 1 | 2025 |
Source payment records
|
|||||
| BRIXADI Normalized: brixadi |
Drug | Braeburn Inc. | $20.49 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $20.39 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $18.57 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 314 | 66 |
| Lisinopril | Lisinopril | 192 | 43 |
| Levothyroxine Sodium | Levothyroxine Sodium | 189 | 32 |
| Potassium Chloride | Potassium Chloride | 173 | 38 |
| Gabapentin | Gabapentin | 161 | 40 |
| Omeprazole | Omeprazole | 152 | 27 |
| Losartan Potassium | Losartan Potassium | 132 | 29 |
| Trazodone Hcl | Trazodone Hcl | 128 | 24 |
| Amlodipine Besylate | Amlodipine Besylate | 119 | 20 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 116 | 28 |
| Famotidine | Famotidine | 113 | 21 |
| Furosemide | Furosemide | 113 | 23 |
| Pantoprazole Sodium | Pantoprazole Sodium | 112 | 27 |
| Metoprolol Succinate | Metoprolol Succinate | 106 | 26 |
| Simvastatin | Simvastatin | 101 | 21 |
| Sertraline Hcl | Sertraline Hcl | 96 | 17 |
| Eliquis | Apixaban | 91 | 16 |
| Lorazepam | Lorazepam | 91 | 19 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 86 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 79 | 19 |
| Metformin Hcl | Metformin Hcl | 77 | 16 |
| Metoprolol Tartrate | Metoprolol Tartrate | 76 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 75 | 17 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 72 | 33 |
| Tamsulosin Hcl | Tamsulosin Hcl | 72 | 11 |
| Tramadol Hcl | Tramadol Hcl | 72 | 11 |
| Januvia | Sitagliptin Phosphate | 71 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 66 | 15 |
| Pregabalin | Pregabalin | 66 | 18 |
| Clonazepam | Clonazepam | 63 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 61 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 59 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 54 | suppressed |
| Spironolactone | Spironolactone | 53 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 52 | suppressed |
| Prednisone | Prednisone | 51 | 26 |
| Ozempic | Semaglutide | 46 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 45 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 45 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 44 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 44 | suppressed |
| Alprazolam | Alprazolam | 43 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 43 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 43 | suppressed |
| Myrbetriq | Mirabegron | 41 | suppressed |
| Aripiprazole | Aripiprazole | 40 | suppressed |
| Finasteride | Finasteride | 40 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 40 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 39 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 37 | suppressed |
| Fentanyl | Fentanyl | 37 | suppressed |
| Mirtazapine | Mirtazapine | 37 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 37 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 36 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 36 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 35 | suppressed |
| Olanzapine | Olanzapine | 35 | suppressed |
| Bupropion Xl | Bupropion Hcl | 34 | suppressed |
| Ezetimibe | Ezetimibe | 34 | suppressed |
| Glipizide | Glipizide | 34 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 34 | suppressed |
| Methocarbamol | Methocarbamol | 33 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 33 | suppressed |
| Atenolol | Atenolol | 32 | suppressed |
| Buprenorphine | Buprenorphine | 32 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 32 | suppressed |
| Lamotrigine | Lamotrigine | 32 | suppressed |
| Baclofen | Baclofen | 31 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 30 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 29 | 11 |
| Buspirone Hcl | Buspirone Hcl | 28 | suppressed |
| Trulicity | Dulaglutide | 28 | suppressed |
| Diazepam | Diazepam | 27 | suppressed |
| Methadone Hcl | Methadone Hcl | 27 | suppressed |
| Primidone | Primidone | 27 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 26 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 26 | suppressed |
| Allopurinol | Allopurinol | 25 | suppressed |
| Oxycontin | Oxycodone Hcl | 25 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 25 | suppressed |
| Ibuprofen | Ibuprofen | 24 | 11 |
| Levetiracetam | Levetiracetam | 24 | suppressed |
| Meloxicam | Meloxicam | 23 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 23 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 22 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | suppressed |
| Elmiron | Pentosan Polysulfate Sodium | 22 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 22 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Risperidone | Risperidone | 21 | suppressed |
| Xtampza Er | Oxycodone Myristate | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 20 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 19 | suppressed |
| Jardiance | Empagliflozin | 19 | suppressed |
| Novolog Flexpen | Insulin Aspart | 19 | suppressed |
| Praluent Pen | Alirocumab | 19 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 18 | suppressed |
| Lacosamide | Lacosamide | 18 | suppressed |
| Sucralfate | Sucralfate | 18 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 18 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 17 | suppressed |
| Eszopiclone | Eszopiclone | 16 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 16 | suppressed |
| Carvedilol | Carvedilol | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 14 | 11 |
| Butrans | Buprenorphine | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Clozapine | Clozapine | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Norethindrone | Norethindrone | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Repatha Sureclick | Evolocumab | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | suppressed |
| Azathioprine | Azathioprine | 12 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 12 | suppressed |
| Oxazepam | Oxazepam | 12 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Dupixent Pen | Dupilumab | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $83.89 · 4 records | Otsuka America Pharmaceutical, Inc. | BRIXADI, CAPLYTA, REXULTI, The Cologuard Plus Collection Kit | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error